Scott W. Hiebert

Vanderbilt University — United States

Medicine · Health Sciences

76h-index23.7kcitations294works3.42yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Acute Myeloid Leukemia Research(81), Protein Degradation and Inhibitors(69), Histone Deacetylase Inhibitors Research(64), Cancer-related gene regulation(42), Epigenetics and DNA Methylation(41)

Publications294 total

Mtg16 NHR1 mutations cause defects in lymphopoiesis and the response to anemia
Experimental Hematology·2025
eNRSA: a faster and more powerful approach for nascent transcriptome analysis
GigaScience·2025Open Access
Expression-Driven Genetic Dependency Reveals Targets for Precision Medicine
2024· 1 citedOpen Access
MTGR1 is required to maintain small intestinal stem cell populations
Cell Death and Differentiation·2024· 4 citedOpen Access
Mutant FOXO1 controls an oncogenic network via enhancer accessibility
Cell Genomics·2024· 4 citedOpen Access
Histone deacetylases maintain expression of the pluripotent gene network via recruitment of RNA polymerase II to coding and noncoding loci
Genome Research·2024· 15 citedOpen Access
Oncologic outcomes of interventions minimizing ischemia-reperfusion injury during transplant for HCC
HPB·2024Open Access
Jedi‐1/MEGF12‐mediated phagocytosis controls the pro‐neurogenic properties of microglia in the ventricular‐subventricular zone
Alzheimer s & Dementia·2023Open Access
MTGR1 is required to maintain small intestinal stem cell populations
2023· 1 citedOpen Access
Chemical-genetics refines transcription factor regulatory circuits
Trends in cancer·2023· 7 citedOpen Access
Myo-differentiation reporter screen reveals NF-Y as an activator of PAX3–FOXO1 in rhabdomyosarcoma
Proceedings of the National Academy of Sciences·2023· 15 citedOpen Access
A dual indexed approach to small RNA sequencing library preparation for PRO-seq
2023Open Access
Abstract 6274: Preclinical characterization of the BET inhibitor, INCB057643, in combination with ruxolitinib for treatment of myeloproliferative neoplasms (MPN)
Cancer Research·2023
Supplementary Figures S1 - S14 from <i>CREBBP</i> Inactivation Promotes the Development of HDAC3-Dependent Lymphomas
2023Open Access
Supplementary Table S6 from <i>CREBBP</i> Inactivation Promotes the Development of HDAC3-Dependent Lymphomas
2023Open Access
Data from <i>CREBBP</i> Inactivation Promotes the Development of HDAC3-Dependent Lymphomas
2023Open Access
Supplementary Table S3 from <i>CREBBP</i> Inactivation Promotes the Development of HDAC3-Dependent Lymphomas
2023Open Access
Supplementary Table S1 from <i>CREBBP</i> Inactivation Promotes the Development of HDAC3-Dependent Lymphomas
2023Open Access
Supplementary Table S4 from <i>CREBBP</i> Inactivation Promotes the Development of HDAC3-Dependent Lymphomas
2023Open Access
Supplementary Table S4 from <i>CREBBP</i> Inactivation Promotes the Development of HDAC3-Dependent Lymphomas
2023Open Access
page 1 of 15Next →

Frequent Co-authors

Bart Lutterbach(8), James R. Downing(6), Srividya Bhaskara(6), Jane B. Lian(6), Joseph R. Nevins(5), Janet L. Stein(5), Gary S. Stein(5), Shari Meyers(5), Jennifer J. Westendorf(4), Noel Lenny(4), Joseph M. Amann(4), Ari Melnick(4), André J. van Wijnen(4), Maria Mudryj(3), Janet D. Rowley(3), Samuel P. Meyers(3), Bryan Linggi(3), Christopher J. Hetherington(3), Daniel G. Tenen(3), Sarah K. Knutson(3)